Abstracts tagged "systemic lupus erythematosus (SLE) and transcription factor"

Abstract Number: 3020 • 2015 ACR/ARHP Annual Meeting
IL-21 Abrogates CD4+CD25+FOXP3+ Treg Differentiation in Part By Suppressing Treg GATA-3 Expression in SLE
Hiroshi Kato¹ and Andras Perl², ¹Division of Rheumatology/Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, ²Department of Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Previous studies point to qualitative and quantitative Treg insufficiencies underlying aberrant T-cell activation in SLE. GATA-3 is critical in lineage commitment and functions of…
Abstract Number: 1033 • 2014 ACR/ARHP Annual Meeting
Stat3 Promotes IL-10 Expression in SLE T Cells through Trans-activation and Chromatin Remodeling
Christian Hedrich¹, Thomas Rauen², Sokratis Apostolidis³, Alexandros P. Grammatikos⁴, Noe Rodriguez Rodriguez⁴, Christina Ioannidis³, Vasileios C. Kyttaris⁴, José C. Crispin⁴ and George C. Tsokos⁵, ¹Children's Hospital, Dresden, Germany, ²Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA, ³Medicine, Rheumatology, BIDMC, Boston, MA, ⁴Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁵Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: IL-10 is an immune-regulatory cytokine that is expressed by a wide range of cells and tissues. It plays a central role in the regulation…
Abstract Number: 2699 • 2013 ACR/ARHP Annual Meeting
Transcription Factor RFX1 Regulates Th17 Differentiation and Its Role In The Pathogenesis Of Systemic Lupus Erythematosus
Ming Zhao¹, Gongping Liang¹, Qian Tang², Yang Yang¹, Yixin Tan¹ and Qianjin Lu¹, ¹Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, ²Second Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: Recently, evidence is emerging that abnormal regulation of Th17 differentiation plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). However, the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].